Back to top
more

HMS Holdings Corp (HMSY)

(Delayed Data from NSDQ)

$32.83 USD

32.83
1,261,295

+3.43 (11.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $32.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ecolab's AdvaCare Disinfectant Receives First EPA Approval

by Zacks Equity Research

Ecolab's (ECL) AdvaCare Disinfectant receives first EPA approval for a laundry disinfectant and oxidizer emerging viral pathogen claim that is effective against the coronavirus.

Here's Why You Should Retain AmerisourceBergen Stock Now

by Zacks Equity Research

Investor confidence is high on AmerisourceBergen (ABC) stock, thanks to solid prospects.

Here's Why You Should Retain Ecolab in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Ecolab (ECL) stock, thanks to solid prospects.

Why You Should Retain PerkinElmer (PKI) in Your Portfolio

by Zacks Equity Research

PerkinElmer (PKI) continues to gain traction from strong international presence and robust product portfolio.

ABIOMED's (ABMD) Impella RP Receives FDA's EUA Clearance

by Zacks Equity Research

This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product portfolio.

Cerner & NCHC Alliance to Boost Behavioral Health Technology

by Zacks Equity Research

Cerner (CERN) has been selected by NCHC to implement its EHR across three multi-specialty facilities.

Here's Why You Should Add Accuray to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Accuray (ARAY) stock, thanks to solid prospects.

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

by Zacks Equity Research

DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.

Here's Why You Should Invest in OPKO Health (OPK) Stock Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain traction from solid prospects in RAYALDEE and BioReference platforms.

Here's Why You Should Retain Inogen in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high in Inogen (INGN) stock, thanks to solid prospects.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from broad product portfolio and persistent focus on R&D. However, forex remains a woe.

Varian (VAR) Unveils New Features for Noona Software

by Zacks Equity Research

This development, which is in response to the challenges brought on by the pandemic, is expected to boost Varian's (VAR) Oncology segment.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Baxter Receives CE Marking for Evo IQ Syringe Infusion System

by Zacks Equity Research

Baxter (BAX) receives the CE marking and regulatory approval for the Evo IQ Syringe Infusion system that will help in optimizing efficiency for clinicians.

Here's Why You Should Add Surmodics to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.

Cerner and Hospital IQ Partner to Boost Clinical Awareness

by Zacks Equity Research

Cerner (CERN) partners with Hospital IQ to help health systems with predictive analytics to enhance clinical and operational awareness.

Veeva Systems Boosts Product Portfolio With New Application

by Zacks Equity Research

Veeva Systems (VEEV) announces a new application called MyVeeva to enable patient-centric clinical trials.

Here's Why You Should Retain Merit Medical (MMSI) for Now

by Zacks Equity Research

Investor confidence is high in Merit Medical (MMSI) stock, thanks to solid prospects.

OPKO's BioReference Laboratories' Deal Brings Antibody Testing

by Zacks Equity Research

OPKO Health's (OPK) subsidiary, BioReference Laboratories collaborates with MagnaCare to offer antibody testing to Labor groups in New York metropolitan area.

HMSY or TRHC: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HMSY vs. TRHC: Which Stock Is the Better Value Option?

Here's Why You Should Retain Avanos Medical Stock for Now

by Zacks Equity Research

Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, stiff competition remains a concern.

Nevro's (NVRO) Senza Omnia SCS System Gets CE Mark Approval

by Zacks Equity Research

Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.

ResMed Grows on Solid Ventilator Sales Amid Coronavirus Woes

by Zacks Equity Research

ResMed (RMD) global sales increase on ramped-up demand for its critical care support products.

Here's Why You Should Retain Cardinal Health Stock for Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.

HMS Holdings (HMSY) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

HMS Holdings (HMSY) witnessed revenue growth at COB and PI segments in Q1.